Clinical analysis of concurrent chemoradiotherapy

Authors: Zhihua Sun Qinfeng Li Zhenyu Li Yeshan Chen Yao Jiang Gang Wu

Publish Date: 2012/01/10

Volume: 11, Issue: 1, Pages: 1-5

PDF Link

Abstract

83 cases of patients who have been diagnosed for locally advanced NSCLC by determined cytology or pathology were divided into two groups randomly 42 patients in NP group and 41 patients in EP group All patients accepted thoracic threedimensional conformal radiotherapy 3DCRT and concurrent either NP chemotherapy in NP group or EP chemotherapy in EP group 3DCRT were started on day 1 in the first cycle of chemotherapy Chemotherapy were carried out for 4 cycles every cycle was 21 days Thoracic radiotherapy adopted conventional fractionated irradiation with 15 MeVX ray a total dose of 60 GyIn 83 patients were evaluable there were 5 cases complete regression to be observed 29 cases had partial regression PR 7 cases with stable disease SD and 1 case with progression disease PD in NP group CR 3 cases PR 27 cases SD 9 cases and PD 2 cases in EP group The overall response rate RR both NP group and EP group were 809 732 respectively P = 07851 2 3year survival rate were 905 690 286 and 829 512 219 respectively P = 0393 The incidence of leukopenia and thrombocytopenia in NP group was higher than that in the EP group P 005CCRT in patients with locally advanced nonsmall cell lung cancer 3DCRT with concurrent NP or EP chemotherapy 1 2 3year overall survival OS and average survival time AST were not statistically differences a higher incidence of toxicities were observed in NP group but can be tolerable

Keywords: